In the landscape of modern medicine, cardiovascular disease remains the leading cause of mortality worldwide. For decades, the cornerstone of heart attack prevention has been a reliance on standardized risk-assessment calculators and the monitoring of overt symptoms. However, a groundbreaking new study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that these traditional gatekeepers are failing a staggering number of patients.
Published on November 21 in the Journal of the American College of Cardiology: Advances, the study reveals that commonly used cardiac screening methods—specifically the ASCVD (Atherosclerotic Cardiovascular Disease) risk score and the newer PREVENT tool—fail to identify nearly half of the individuals who are at imminent risk of a heart attack. The findings represent a critical indictment of current clinical guidelines, suggesting that the medical community may be inadvertently leaving millions of "low-risk" patients vulnerable to life-altering cardiac events.
The Illusion of Safety: Analyzing Current Risk Models
For years, primary care physicians have utilized the ASCVD risk score to make life-or-death decisions. Designed for adults aged 40 to 75 without known heart disease, this tool calculates the 10-year probability of a heart attack or stroke based on a set of traditional variables: age, sex, race, blood pressure, cholesterol levels, diabetes status, and smoking history.
More recently, the medical community introduced the PREVENT risk tool, which aims to improve upon the ASCVD model by incorporating a broader array of variables. The objective of both tools is to categorize patients into risk brackets—low, borderline, intermediate, or high—to determine who should receive aggressive preventive interventions, such as cholesterol-lowering statin therapy or advanced diagnostic imaging.
However, the Mount Sinai study suggests that these calculators operate on a fundamental misunderstanding of individual pathology. "Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients," explains Dr. Amir Ahmadi, the study’s corresponding author and a Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai.
The study’s findings are stark: if these same patients had been evaluated just 48 hours before their heart attack, nearly half would not have met the criteria for preventive therapy under current guidelines. In the case of the newer PREVENT tool, that number climbed to over 60 percent.
Chronology of the Investigation: A Retrospective Analysis
To test the efficacy of these screening tools, the research team conducted a rigorous retrospective analysis involving 474 patients. The cohort consisted of individuals under the age of 66 who had no prior diagnosis of coronary artery disease. All participants were treated for a first-time heart attack at either Mount Sinai Morningside or The Mount Sinai Hospital between January 2020 and July 2025.
The investigation was structured as a "reverse-engineered" clinical scenario. Researchers compiled comprehensive demographic data, medical histories, blood pressure readings, and cholesterol panels for every participant. They then cross-referenced this data with the timing of the patients’ initial symptoms—specifically, when they first experienced warning signs like chest pain or shortness of breath.
By calculating the 10-year risk score for each patient as it would have appeared two days before their cardiac event, the team was able to simulate a routine primary care visit. The goal was to determine if a physician, using standard guidelines, would have flagged these individuals as "at risk" and initiated preventative care or further diagnostic testing. The results, as noted, were deeply concerning, revealing that a large majority of these heart attack victims would have been categorized as low or borderline risk, effectively flying under the medical radar until their condition turned critical.
The Symptom Paradox: Why "Wait and See" Is Failing
A primary pillar of current clinical practice is the triage of patients based on reported symptoms. If a patient presents with no chest pain, no shortness of breath, and a low risk score, they are often reassured and discharged without further evaluation. This study, however, demonstrates that this approach is fundamentally reactive rather than preventative.
Data from the cohort revealed that 60 percent of the patients experienced their first symptoms fewer than two days before their heart attack. This indicates that by the time a patient actually reports symptoms, the underlying pathology—atherosclerosis—is often already in an advanced state.
"This study suggests that the current approach of relying on risk scores and symptoms as primary gatekeepers for prevention is not optimal," Dr. Ahmadi asserts. "It may be time to fundamentally reconsider this model and move toward atherosclerosis imaging to identify the silent plaque—early atherosclerosis—before it has a chance to rupture."
The "silent plaque" phenomenon is the crux of the issue. Atherosclerosis, the buildup of fats, cholesterol, and other substances in and on the artery walls, can progress for years without manifesting as a physical sensation. Traditional risk scores are excellent at identifying broad trends across large populations, but they are often blind to the presence of specific, vulnerable plaque deposits in an individual artery.
Supporting Data: The Failure of Categorization
The statistical breakdown of the study provides a sobering look at how current tools categorize patients. Under the ASCVD guidelines, 45 percent of the patients in the study would have been classified as "low" or "borderline" risk. When the newer, supposedly more robust PREVENT tool was applied to the same group, the failure rate increased to 61 percent.
These individuals, who would have been told they were at minimal risk of a major cardiac event, were, in reality, on the brink of a life-threatening incident. The findings illustrate a dangerous "prevention gap" where the criteria for receiving life-saving interventions are too narrow, excluding patients who are clinically asymptomatic but biologically unstable.
The study also highlights that the traditional "intermediate risk" category—which often triggers a discussion about statins—is also prone to missing a significant portion of patients who go on to have heart attacks. The data suggests that many heart attacks occur in the low-to-intermediate risk groups, rendering the current classification system a poor predictor of individual outcomes.
Official Responses and Clinical Implications
The implications of this study are far-reaching. Dr. Anna Mueller, the study’s first author and an internal medicine resident at the Icahn School of Medicine at Mount Sinai, emphasizes that the issue is not necessarily the math behind the risk scores, but how those scores are used to gatekeep care.
"When we look at heart attacks and trace them backwards, most occur in patients in the low or intermediate risk groups," Dr. Mueller explains. "This study highlights that a lower risk score, along with not having classic heart attack symptoms, is no guarantee of safety on an individual level."
For the medical community, the message is clear: the paradigm must shift. Relying on aggregate population statistics is insufficient for modern personalized medicine. The authors advocate for a move toward direct imaging of the coronary arteries. By utilizing advanced imaging techniques, physicians can identify the presence of plaque directly, regardless of whether a patient’s risk score falls into the "low" or "high" category.
This approach, known as detecting "silent atherosclerosis," could revolutionize how doctors prevent heart attacks. Instead of waiting for a risk score to hit a certain threshold or for a patient to complain of chest pain, clinicians could treat the underlying physical disease as soon as it is detected via imaging.
Moving Toward a New Standard of Care
While the study is a clarion call for change, the researchers acknowledge that the transition to an imaging-heavy model of care will require further investigation. Refining these methods and establishing new clinical guidelines will be a complex process, involving cost-benefit analyses, insurance coverage adjustments, and updated training for primary care providers.
However, the cost of inaction is too high to ignore. With heart disease continuing to claim millions of lives annually, the reliance on outdated, symptomatic-driven, and broad-spectrum risk assessment models is no longer defensible. As the Mount Sinai team continues their work, they hope that these findings will act as a catalyst for a broader movement within cardiology—one that prioritizes the direct identification of silent plaque over the statistical estimation of risk.
In the future, the goal is to reach a point where "low risk" is not merely a statistical probability calculated on a clipboard, but a verified physiological status confirmed by clinical evidence. Until then, the medical community faces the daunting task of reconciling the limitations of current tools with the urgent need to protect patients who appear healthy but are, in fact, walking toward a medical crisis. The findings released by the Mount Sinai team serve as a necessary, if uncomfortable, reminder that in the fight against heart disease, the absence of symptoms is not the same as the absence of illness.
